Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
12
NCT04019288
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase 1/2
Role: Collaborator
Start: Dec 3, 2019
Completion: Oct 24, 2024